SOC Treatment

OTHER4 trials

Sponsors

BONESUPPORT AB, ModernaTX, Inc., Janssen Research & Development, LLC

Conditions

Influenza ASolid TumorsTibial Fracture

Phase 1

Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors

Active, not recruitingNCT03313778

ModernaTX, Inc.Solid Tumors

Start: 2017-08-14End: 2027-11-21Updated: 2026-03-04

Phase 3

A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Hospitalized Participants With Influenza A Infection

TerminatedNCT03376321

Janssen Research & Development, LLCInfluenza A

Start: 2018-01-03End: 2020-04-30Updated: 2025-02-04

A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Non-Hospitalized Participants With Influenza A Infection Who Are at Risk of Developing Complications

TerminatedNCT03381196

Janssen Research & Development, LLCInfluenza A

Start: 2018-01-21End: 2020-08-24Updated: 2025-02-04

Unknown Phase

Study Evaluating CERAMENT™|G in Open Diaphyseal Tibial Fractures

CompletedNCT02820363

BONESUPPORT ABTibial Fracture

Start: 2017-02-14End: 2021-07-31Updated: 2021-08-10

Related Papers

Immunogenicity and Efficacy of Personalized Adjuvant mRNA Cancer Vaccines

Cancer Discovery2024-11-017 citations

Efficacy and Safety of Pimodivir Combined With Standard of Care in Hospitalized and Nonhospitalized High-Risk Adolescents and Adults With Influenza A Infection

The Journal of Infectious Diseases2024-08-225 citations

T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study

Cancer Discovery2024-08-0875 citations

Abstract CT141: mRNA-4157 (V940) individualized neoantigen therapy (INT) + pembrolizumab (pembro) in advanced unresectable HPV- head & neck carcinoma (HNSCC): Clinical & translational analysis

Cancer Research2024-04-053 citations

A Phase 2 Study of Pimodivir (JNJ-63623872) in Combination With Oseltamivir in Elderly and Nonelderly Adults Hospitalized With Influenza A Infection: OPAL Study.

2022-08-0123 citations

798 Safety, tolerability, and immunogenicity of mRNA-4157 in combination with pembrolizumab in subjects with unresectable solid tumors (KEYNOTE-603): an update

2020-11-0152 citations

A phase I multicenter study to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone in patients with resected solid tumors and in combination with pembrolizumab in patients with unresectable solid tumors.

Journal of Clinical Oncology2019-05-20132 citations